Policy Summary
Privacy policy
This static site is designed to minimize data collection. CTA links may pass UTM parameters to third-party websites.
Key standards
This static site is designed to minimize data collection. CTA links may pass UTM parameters to third-party websites.
Compounded tirzepatide and compounded semaglutide are not FDA-approved as finished drugs. They may be prescribed only when a licensed provider determines they are clinically appropriate and legally permissible for an individual patient. Brand-name medications such as Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved products and should not be treated as identical to compounded medications.
Frequently asked questions
Can I request a correction?
Yes. Use the contact page or correction policy to request a source or pricing correction.
Is this medical advice?
No. The site is informational only and does not replace licensed medical advice.
Sources
- FDA GLP-1 compounding policy clarification (Regulator)
- FDA Compounding and the FDA: Questions and Answers (Regulator)
- FDA 503B bulks list proposal for GLP-1 drugs (Regulator)
- Zepbound prescribing information (Label)
- Wegovy prescribing information (Label)
- NexLife tirzepatide pricing page (Provider pricing)
- NexLife FAQ pricing page (Provider pricing)
- NexLife semaglutide pricing page (Provider pricing)